<DOC>
	<DOCNO>NCT02657915</DOCNO>
	<brief_summary>The primary objective study ass full-field visual evoke potential ( FF-VEP ) latency subject enrol Study 215ON201 ( NCT01721161 ) 2 year ( + 4 month ) last study visit . The secondary objective ass clinical progression severity central nervous system ( CNS ) demyelinate disease subject enrol Study 215ON201 2 year ( + 4 month ) last study visit . No study drug dose plan study .</brief_summary>
	<brief_title>Long-Term Assessment Remyelinating Therapy</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>Key Must participate Study 215ON201 receive least 1 dose BIIB033 placebo , per protocol , within 2 year ( + 4 month ) Day 1 study ( 2 year Week 32 project Week 32 visit , subject complete visit Study 215ON201 ) . Key Not previously enrol Study 215ON201 Subjects recent kidney function , serum creatinine upper limit normal range , allow receive administration Gd otherwise allow participate study , include magnetic resonance imaging ( MRI ) assessment require use Gd . Female subject must recent pregnancy test must breastfeed prior MRI assessment Gd . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FF-VEP</keyword>
	<keyword>mfVEP</keyword>
	<keyword>Human anti-LINGO-1</keyword>
	<keyword>BIIB033</keyword>
	<keyword>AON</keyword>
</DOC>